Cjc 1295 Ipamorelin vs Tesamorelin: Comparing the Indexed Record
A working comparison of Cjc 1295 Ipamorelin against Tesamorelin begins with the indexed literature, not with catalogue description.
Compound profiles
Cjc 1295 Ipamorelin in the indexed record
Cjc 1295 Ipamorelin returns 10 indexed records on PubMed, a limited record with no registered studies currently listed on ClinicalTrials.gov.
Publications carrying this compound include Am J Sports Med, Int J Mol Sci, J Am Acad Orthop Surg Glob Res Rev.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine — Am J Sports Med, 2026. PMID: 42578445
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives — Int J Mol Sci, 2026. PMID: 42123471
Tesamorelin in the indexed record
The literature on Tesamorelin is a moderate body of work: 121 PubMed-indexed records, alongside 24 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Ann Pharmacother, BETA, Curr Opin Investig Drugs, spanning 2006–2012.
- Tesamorelin — , 2012. PMID: 31644039
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother, 2012. PMID: 22298602
- Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs, 2009. PMID: 19243281
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs, 2011. PMID: 21668043
Side-by-side research profile
| Parameter | Cjc 1295 Ipamorelin | Tesamorelin |
|---|---|---|
| PubMed indexed records | 10 | 121 |
| Registered studies (ClinicalTrials.gov) | 0 | 24 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Cjc 1295 Ipamorelin and Tesamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Cjc 1295 Ipamorelin describes conditions validated for Cjc 1295 Ipamorelin: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tesamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. Tesamorelin carries 111 more indexed records than Cjc 1295 Ipamorelin, which means published methodology, characterisation data and replication attempts are more readily located for Tesamorelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 24) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Selecting between them for a study design
Cjc 1295 Ipamorelin and Tesamorelin are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Tesamorelin) generally offers more methodological precedent.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Frequently asked questions
Are Cjc 1295 Ipamorelin and Tesamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 10 indexed records for Cjc 1295 Ipamorelin and 121 for Tesamorelin.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- Tesamorelin — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.